Sanofi and GSK launch trial for protein-based coronavirus vaccine

Topics Sanofi  | Sanofi India | Coronavirus


PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world. This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza.....

This article is no longer available in our repository.

There could be multiple reasons for this.